Positive late-stage results revive hopes for FDA approval in erythropoietic protoporphyria after a prior regulatory setback.

Late-stage data for the next-generation obesity candidate supports Novo's pipeline as competition in the market intensifies.

The order raises the prospect of higher drug costs and supply chain shifts for import-dependent manufacturers.

The NPPA margin cap is expected to sharply cut oncology treatment costs in India while industry groups seek a broader pricing review.

Direct price cuts and growing supply are reshaping the economics of the US obesity market.

The move marks a retreat from one obesity pipeline asset as Pfizer reassesses its cardiometabolic strategy.

The larger REGAIN study moves forward with new data due at the SNO 2026 annual meeting.

Trial showed 85% of men reporting better coverage versus 35.3% on placebo, extending the company's run of late-stage successes.

The close vote sets up a decision on whether compounded versions of popular peptides can remain legally available.

The approval expands GSK's PD-1 use into MSI-H/dMMR locally advanced rectal cancer.

A recall follows regulatory scrutiny of compounded GLP-1 copycats sold outside the branded supply chain.

The pricing watchdog's assessment adds pressure on manufacturers as launch prices keep rising relative to benefit.

Manufacturers warn the widening repricing will erode incentives for Japanese drug development.

The regulatory acceptance moves the candidate toward a possible approval decision, with a 77.8% complete response rate reported at three months.

The obesity drug launch is seen as key to a rebound amid governance disputes at the Korean company.

The trial failure triggers a deep restructuring at the ophthalmology-focused biotech.

The approval clears a production pathway for the biosimilar maker's Humira copy.

Five short talks will cover liquid biopsy data, a key battleground in early cancer detection.